Alcami Appoints President of Laboratory Operations
17 Feb 2023
Executive Change
WILMINGTON, N.C., Feb. 17, 2023 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the promotion of Katie Schlipp to President of Laboratory Operations.
Katie brings over 25 years of experience in leading laboratory teams. She started her career with AAIPharma (now Alcami) as an Assistant Scientist in Wilmington, NC, and progressed through every level of the scientific and management career ladder culminating in her appointment as President.
As President of Laboratory Operations, Katie is responsible for Alcami's extensive laboratory network spanning four campus locations offering comprehensive analytical development and method establishment, QC release and stability testing, microbiology, and identification/characterization to support both small molecules and biologics. Katie holds a Bachelor's and Master's of Chemistry from the University of North Carolina at Wilmington.
"During her tenure at Alcami, Katie instituted 5S and lean principles, Key Performance Indicators (KPIs), and implemented training and mentoring solutions within our laboratory operation, which is widely recognized today as one of the top analytical service labs in the world," commented Chairman and CEO Patrick Walsh. "Katie's proven track record of leading client-focused laboratory operations makes her the ideal choice to lead Alcami's next phase of laboratory operations growth and expansion."
About Alcami Corporation
Alcami is a contract development and manufacturing organization headquartered in North Carolina with over 40 years of experience advancing products through every stage of the development lifecycle. Leveraging 675,000 ft² across five US-based scientific campuses, Alcami serves pharmaceutical and biotech companies of all sizes for small molecules and biologics, providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid dose drug product manufacturing, packaging, microbiology, cGMP biostorage, environmental monitoring, and pharmaceutical support services. Alcami's private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit alcaminow.com.
View original content to download multimedia:
SOURCE Alcami Corporation
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.